PROCEPT BioRobotics Announces 12 Scientific Research Presentations on Aquablation Therapy for the Treatment of Benign Prostatic Hyperplasia at the 2024 AUA Annual Meeting

Presentations include first published experience report of same-day discharge in an ambulatory surgical center, real-world data outcomes and 5-year data comparison between two FDA trials

SAN JOSE, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that 12 abstracts highlighting its Aquablation therapy for the treatment of benign prostatic hyperplasia (BPH) will be presented at the American Urological Association (AUA) Annual Meeting in San Antonio, Texas, from May 3 - 6, 2024. PROCEPT BioRobotics is exhibiting at booth #1429 and will be conducting hands-on workshops and surgeon presentations throughout the meeting.

“The growing body of real-world clinical evidence on Aquablation therapy is reflected by the extensive range of presentations being showcased at the AUA,” said Reza Zadno, CEO of PROCEPT BioRobotics. “Aquablation therapy, one of the fastest growing robotics platforms, is the only BPH treatment that offers significant durable symptom relief while preserving sexual function and continence across prostates of all shapes and sizes. The continued momentum and interest in Aquablation therapy are a testament to our unwavering commitment to advancing innovative, safe and effective treatment options for patients.”

Registered attendees can access the full list of Aquablation therapy presentations here. Highlights include:

Friday, May 3, 2024
3:30 – 5:30 pm

• MP20-01: WATER vs WATER II 5-Year Update: Comparing Aquablation Therapy for Benign Prostatic Hyperplasia in 30-80 cc and 80-150 cc Prostates
  Mohamad Baker Berjaoui, MD
  University of Toronto
  This study presents the final analysis comparing clinical trial outcomes of Aquablation to TURP for the treatment of lower urinary tract symptoms (LUTS) in small-to-moderate prostates (WATER study: NCT02505919) to those in large prostates (WATER II: NCT03123250) at five-year follow-up.

• MP: 20-03: Aquablation Real-World Prostate Size Utilization and Reported Bleeding Events Across 5 Years
  Dean Elterman, MD, MSc, FRCSC
  University of Toronto
  While clinical studies in the past have evaluated Aquablation therapy’s application in glands between 30-150mL, this study sought to evaluate how the technology is used in the real-world setting. 31,944 procedures were evaluated from 2019-2023 in patients across Asia, Europe and North America.

• MP20-05: Day Case Aquablation: First Published Experience Report in an Ambulatory Surgical Center (ASC)